StreetInsider.com News Articles

Longeveron hires financial advisor to explore strategic options

Wed, 28 Oct 2026 09:15:42 -0400

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company based in Miami, has retained Lucid Capital Markets, LLC as its financial advisor to explore potential strategic opportunities, including a possible business combination, according to a company statement.

The company did not disclose the terms of the engagement or provide a timeline for any potential transaction. Longeveron noted that the exploration of strategic options may not result in any definitive transaction.

Longeveron's lead investigational product is laromestrocel (Lomecel-B), a mesenchymal stem cell therapy derived from bone marrow of adult donors. The therapy is being developed for conditions including hypoplastic left heart syndrome (HLHS) and

Longeveron hires financial advisor to explore strategic options

Wed, 28 Oct 2026 09:15:42 -0400

Longeveron hires financial advisor to explore strategic options

Wed, 28 Oct 2026 09:15:42 -0400

Longeveron hires financial advisor to explore strategic options

Wed, 28 Oct 2026 09:15:42 -0400

Longeveron Announces Engagement of Lucid Capital Markets

Wed, 28 Oct 2026 09:15:00 -0400

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore potential strategic opportunities, including a potential business combination.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms

Longeveron Announces Engagement of Lucid Capital Markets

Wed, 28 Oct 2026 09:15:00 -0400

About Longeveron Inc.

Longeveron Announces Engagement of Lucid Capital Markets

Wed, 28 Oct 2026 09:15:00 -0400

About Longeveron Inc.

Longeveron Announces Engagement of Lucid Capital Markets

Wed, 28 Oct 2026 09:15:00 -0400

About Longeveron Inc.

Form 8-K Longeveron Inc. For: Oct 26

Mon, 26 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261026/27234661.html

Longeveron HLHS trial misses primary goal but shows MACE benefit

Mon, 26 Oct 2026 09:15:25 -0400

Longeveron Inc. (NASDAQ: LGVN) announced updated results from its ELPIS II Phase 2b clinical trial evaluating laromestrocel as an adjunct therapy for infants with hypoplastic left heart syndrome (HLHS), according to a company press release.

The trial, which enrolled 40 infants randomized 1:1 to laromestrocel or standard of care (SOC), did not meet its primary endpoint of change from baseline in right ventricular ejection fraction (RVEF) at 12 months. Mean RVEF decreased by 2.6 percentage points in the SOC group and 3.3 percentage points in the laromestrocel group, with no statistically significant difference between the two groups (p=0.68).

Additional analysis of pre-specified

Longeveron HLHS trial misses primary goal but shows MACE benefit

Mon, 26 Oct 2026 09:15:25 -0400

Additional analysis of pre-specified

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Mon, 26 Oct 2026 09:15:00 -0400

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data
Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)
Laromestrocel was associated with fewer adjudicated clinical and

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Mon, 26 Oct 2026 09:15:00 -0400

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data
Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)
Laromestrocel was associated with fewer adjudicated clinical and

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Mon, 26 Oct 2026 09:15:00 -0400

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data
Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)
Laromestrocel was associated with fewer adjudicated clinical and

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Mon, 26 Oct 2026 09:15:00 -0400

ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions

As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional data
Additional analysis demonstrates an important pre-specified secondary clinical outcome endpoint, major adverse cardiac events (MACE), achieved statistical significance with 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)
Laromestrocel was associated with fewer adjudicated clinical and

Form 8-K Longeveron Inc. For: Oct 07

Wed, 14 Oct 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20261014/27187066.html

Form 4 Longeveron Inc. For: Oct 01 Filed by: Lehr Paul T

Mon, 05 Oct 2026 18:00:00 -0400
si-local-file:///var/storage/secattach/20261005/27150221.html

Form 4 Longeveron Inc. For: Oct 01 Filed by: Agafonova Nataliya

Mon, 05 Oct 2026 18:00:00 -0400
si-local-file:///var/storage/secattach/20261005/27150223.html

Form 4 Longeveron Inc. For: Oct 01 Filed by: Blass Devin

Mon, 05 Oct 2026 18:00:00 -0400
si-local-file:///var/storage/secattach/20261005/27150225.html

Form 4 Longeveron Inc. For: Oct 01 Filed by: Willard Stephen H

Mon, 05 Oct 2026 18:00:00 -0400
si-local-file:///var/storage/secattach/20261005/27150227.html

Form 4 Longeveron Inc. For: Oct 01 Filed by: Jhaveri Nirav S.

Mon, 05 Oct 2026 18:00:00 -0400
si-local-file:///var/storage/secattach/20261005/27150229.html

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Wed, 30 Sep 2026 16:05:00 -0400

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Wed, 30 Sep 2026 16:05:00 -0400

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Wed, 30 Sep 2026 16:05:00 -0400

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Wed, 30 Sep 2026 16:05:00 -0400

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longevity/Aging investment conferences.

13th Aging Research and Drug Discovery Meeting (ARDD) to be held October 1-3, 2026 in Boston

Abundance Longevity Trip to be held October 7-11, 2026 (virtual participation)

Longevity Partnering Forum to be held October 19-20, 2026